Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
Karolinska University Hospital · Karolinska Institutet · +17 more institutions
Indexed incrossrefpubmed
Abstract
Background
mutations. However, data from randomized trials are lacking.
Methods
(group B alterations) were eligible for randomization. The primary end point was colorectal cancer recurrence, assessed in a time-to-event analysis, in patients with group A alterations. Secondary end points included colorectal cancer recurrence in patients with group B alterations, disease-free survival, and safety.
Citation impact
50
total citations
- FWCI
- 31.64
- Percentile
- 100%
- References
- 25
Citations per year
Authors
19Topics & keywords
Topics
Keywords
- Aspirin
- Colorectal cancer
- Placebo
- Incidence (geometry)
- Clinical trial
- Somatic cell
No related works found for this paper.